Wall Street brokers expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO – Get Rating) to report sales of $25.60 million for the current quarter, according to Zacks. Three analysts provided earnings estimates for AVEO Pharmaceuticals, with the lowest sales estimate of $24.95 million and the highest estimate of $26.04 million. AVEO Pharmaceuticals reported sales of $7.56 million in the same quarter last year, suggesting a positive year-over-year growth rate of 238.6%. The company is due to announce its next earnings report on Monday, January 1.
According to Zacks, analysts expect AVEO Pharmaceuticals to report annual sales of $115.93 million for the current fiscal year, with estimates ranging from $112.00 million to $122.89 million. . For the next fiscal year, analysts expect the company to post sales of $176.64 million, with estimates ranging from $164.50 million to $200.74 million. Zacks sales calculations are an average average based on a survey of analysts who provide coverage for AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO – Get Rating) last released its quarterly results on Thursday, May 5. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.26) by ($0.04). AVEO Pharmaceuticals had a negative return on equity of 90.63% and a negative net margin of 67.57%. The company posted revenue of $20.92 million for the quarter, versus a consensus estimate of $21.33 million. During the same period of the previous year, the company posted an EPS of ($0.72).
AVEO has been the subject of several research analyst reports. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a Thursday, March 17 report. StockNews.com began covering AVEO Pharmaceuticals in a research report on Thursday, March 31. They have placed a “holding” rating on the stock. Finally, Jonestrading began covering AVEO Pharmaceuticals in a research note on Monday, March 14. They issued a “buy” rating on the stock. Two research analysts gave the stock a hold rating and three gave the company a buy rating. According to MarketBeat.com, AVEO Pharmaceuticals currently has a consensus buy rating and an average target price of $18.50.
Shares of AVEO opened at $4.50 on Monday. The company has a market capitalization of $155.15 million, a PE ratio of -3.72 and a beta of 1.19. AVEO Pharmaceuticals has a fifty-two-week low of $3.06 and a fifty-two-week high of $7.59. The stock’s 50-day simple moving average is $4.86 and its 200-day simple moving average is $4.66. The company has a debt ratio of 1.03, a quick ratio of 4.73 and a current ratio of 4.81.
Several large investors have recently bought and sold shares of AVEO. BlackRock Inc. increased its position in shares of AVEO Pharmaceuticals by 11.2% during the third quarter. BlackRock Inc. now owns 532,605 shares of the biopharmaceutical company worth $3,292,000 after purchasing an additional 53,813 shares during the period. Geode Capital Management LLC increased its equity stake in AVEO Pharmaceuticals by 1.8% in the third quarter. Geode Capital Management LLC now owns 249,969 shares of the biopharmaceutical company valued at $1,544,000 after buying 4,324 additional shares last quarter. GSA Capital Partners LLP bought a new position in shares of AVEO Pharmaceuticals in the third quarter at a value of $218,000. Pura Vida Investments LLC increased its equity stake in AVEO Pharmaceuticals by 51.3% in the third quarter. Pura Vida Investments LLC now owns 147,574 shares of the biopharmaceutical company valued at $912,000 after purchasing an additional 50,027 shares last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in AVEO Pharmaceuticals stock in the third quarter worth $207,000. 52.61% of the shares are held by institutional investors.
AVEO Pharmaceuticals Company Profile (Get an assessment)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of drugs for cancer patients. It markets its lead candidate, FOTIVDA, an orally once-daily vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors and ACC.
Get a Free Copy of Zacks’ Research Report on AVEO Pharmaceuticals (AVEO)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for AVEO Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.